Clinical Trial Update: A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent [Phase 4]

View source ↗

Summary

Phase 4 trial assessing DARZALEX (daratumumab) in Indian participants with relapsed and refractory multiple myeloma who had prior proteasome inhibitor and immun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Sponsor: Johnson & Johnson Private Limited | Conditions: Multiple Myeloma | Phase 4 | Status: COMPLETED